The production of recombinant pharmaceutical proteins in plants

Nature Reviews Genetics

Volumn 4, Issue 10, 2003, Pages 794-805

  Ma, Julian K C ^a   Drake, Pascal M W ^a   Christou, Paul ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; AVICIDIN; CAPSID PROTEIN; CARORX; CHOLERA TOXIN; CHOLERA TOXIN A2 SUBUNIT; CHOLERA TOXIN B SUBUNIT; ENTEROTOXIN; ESCHERICHIA COLI ENTEROTOXIN; HEPATITIS B SURFACE ANTIGEN; HEPATITIS E ANTIGEN; MONOCLONAL ANTIBODY T84.66; PORCINE TRANSMISSIBLE GASTROENTERITIS VIRUS GLYCOPROTEIN S; RECOMBINANT ANTIBODY; RECOMBINANT PROTEIN; ROTAVIRUS ENTEROTOXIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; WATER;

CLINICAL TRIAL; DENTAL CARIES; DIARRHEA; DNA MODIFICATION; HUMAN; NONHUMAN; PLANT NUTRITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SUNLIGHT;

ANIMALS; HUMANS; PHARMACEUTICAL PREPARATIONS; PLANTS; PLANTS, GENETICALLY MODIFIED; RECOMBINANT PROTEINS; TECHNOLOGY, PHARMACEUTICAL; TRANSGENES;

ESCHERICHIA COLI; ROTAVIRUS; SUIDAE; TRANSMISSIBLE GASTROENTERITIS VIRUS;

EID: 0141706699     PISSN: 14710056     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrg1177     Document Type: Review

References (111)

1. Schwartz, J. R. Advances in Escherichia coli production of therapeutic proteins. Curr. Opin. Biotechnol. 12, 195-201 (2001).
2. Chu, L. & Robinson, D. K. Industrial choices for protein production by large-scale cell culture. Curr. Opin. Biotechnol. 12, 180-187 (2001).
3. Houdebaine, L. M. Transgenic animal bioreactors. Transgenic Res. 9, 305-320 (2000).
4. Fischer, R. & Emans, N. Molecular farming of pharmaceutical proteins. Transgenic Res. 9, 279-299 (2000).
5. Giddings, G. Transgenic plants as protein factories. Curr. Opin. Biotechnol. 12, 450-454 (2001)
6. Barta, A. et al. The expression of a nopaline synthase human growth hormone chimaeric gene in transformed tobacco and sunflower callus tissue. Plant Mol. Biol. 6, 347-357 (1986).
7. Hiatt, A., Cafferkey, R. & Bowdish, K. Production of antibodies in transgenic plants. Nature 342, 76-78 (1989).
8. Mason, H. S., Lam, D. M. K. & Arntzen, C. J. Expression of hepatitis B surface antigen in transgenic plants. Proc. Natl Acad. Sci. USA 89, 11745-11749 (1992)
9. Thanavala, Y., Yang, Y.-F., Lyons, P., Mason, H. S. & Arntzen, C. J. Immunogenicity of transgenic plant-derived hepatitis B surface antigen. Proc. Natl Acad. Sci USA 92, 3358-3361 (1995).
10. Hood, E. E. et al. Criteria for high-level expression of a fungal laccase gene in transgenic maize. Plant Biotechnol. J. 1, 129-140 (2003).
11. Hood, E. E. et al. Commercial production of avidin from transgenic maize: characterization of transformant, production, processing, extraction and purification. Mol. Breeding 3, 291-306 (1997).
12. Chong, D. K. X. et al. Expression of the human milk protein β-casein in transgenic potato plants. Transgenic Res. 6, 289-296 (1997).
13. Ruggiero, F. et al. Triple helix assembly and processing of human collagen produced in transgenic tobacco plants. FEBS Lett. 469, 132-136 (2000).
14. Staub, J. M. et al. High-yield production of a human therapeutic protein in tobacco chloroplasts. Nature Biotechnol. 18, 333-338 (2000). This report shows that the secreted human protein somatotropin is soluble and biologically active when expressed in tobacco chloroplasts and has correctly formed disulphide bonds.
15. Fernandez-San Millan, A., Mingo-Castel, A., Miller, M. & Daniell, H. A chloroplast transgenic approach to hyper-express and purify human serum albumin, a protein highly susceptible to proteolytic degradation. Plant Biotechnol 1, 77-79 (2003).
16. Moloney, M., Boothe, J. & Van Rooijen, G. Oil bodies and associated proteins as affinity matrices. US Patent 6,509,453 (2003).
17. Chadd, H. E. & Chamow, S. M. Therapeutic antibody expression technology. Curr. Opin. Biotechnol. 12, 188-194 (2001).
18. Ma, J. K. et al. Generation and assembly of secretory antibodies in plants. Science 268, 716-719 (1995). This study shows for the first time that secretory antibodies, with 10 polypeptide chains that represent the products of four genes, can be assembled correctly in transgenic plants. Two rounds of crossing, which involved four singly-transgenic lines, were required to stack all four transgenes in the same plant.
19. Richter, L. J., Thanavala, Y., Arntzen, C. J. & Mason, H. S. Production of hepatitis B surface antigen in transgenic plants for oral immunization. Nature Biotechnol. 18, 1167-1171 (2000).
20. Kapusta, J. et al. A plant-derived edible vaccine against hepatitis B virus. FASEB J. 13, 1796-1799 (1999).
21. Tacket, C. O. et al. Immunogenicity in humans of a recombinant bacterial-antigen delivered in a transgenic potato. Nature Med. 4, 607-609 (1998).
22. Tacket, C. O. et al. Human immune responses to a novel Norwalk virus vaccine delivered in transgenic potatoes. J. Infect. Dis. 182, 302-305 (2000).
23. Chong, D. K. X. & Langridge, W. H. R. Expression of full-length bioactive antimicrobial human lactoferrin in potato plants. Transgenic Res. 9, 71-78 (2000).
24. Zhang, X. Urry, D. W. & Daniell, H. Expression of an environmentally friendly synthetic protein-based polymer in transgenic tobacco plants. Plant Cell Reps. 16, 174-179 (1996)
25. Guda, C., Lee, S. B. & Daniell, H. Stable expression of a biodegradable protein-based polymer in stable tobacco chloroplasts. Plant Cell Reps. 19, 257-262 (2000).
26. Merle, C. et al. Hydroxylated human homotrimeric collagen I in Agrobacterium tumefaciens-mediated transient expression and in transgenic tobacco plant. FEBS Lett. 515, 114-118 (2002).
27. Scheller, J., Guhrs, K. H., Grosse, F. & Conrad, U. Production of spider silk proteins in tobacco and potato Nature Biotechnol. 19, 573-577 (2001).
28. O'Dell, J. T., Nagy, F. & Chua, N. H. Identification of DNA sequences required for activity of the cauliflower mosaic virus 35S promoter. Nature 313, 810-812 (1985).
29. Lawton, M. A. et al. Expression of a soybean β-conclycinin gene under the control of the cauliflower mosaic virus 35S and 19S promoters in transformed petunia tissues. Plant Mol. Biol. 9, 315-324 (1987).
30. Kay, R., Chan, A. Daly, M. & McPherson, J. Duplication of CaMV-35S promoter sequences creates a strong enhancer for plant genes. Science 236, 1299-1302 (1987).
31. Christensen, A. H. & Quail, P. H. Ubiquitin promoter-based vectors for high-level expression of selectable and/or screenable marker genes in monocotyledonous plants. Transgenic Res. 5, 213-218 (1996).
32. Vain, P., Finer, K. R., Engler, D. E., Pratt, R. C. & Flner, J. J. Intron-mediated enhancement of gene expression in maize (Zea mays L.) and bluegrass (Poa pratensis L.). Plant Cell Rep. 15, 489-494 (1996).
33. Stoger E. et al. Cereal crops as viable production and storage systems for pharmaceutical scFv antibodies. Plant Mol. Biol. 42, 583-590 (2000).
34. Artsaenko, O., Kettig, B., Fiedler, U., Conrad, U. & Düring K. Potato tubers as a biofactory for recombinant antibodies. Mol. Breeding 4, 313-319 (1998).
35. Padidam, M. Chemically regulated gene expression in plants. Curr. Opin. Plant Biol. 6, 169-177 (2003).
36. Padidam, M., Gore, M., Lu, D. L. & Smirnova, O. Chemical-inducible, ecdysone receptor-based gene expression system for plants. Transgenic Res. 12, 101-109 (2003).
37. Cramer C. L., Boothe, J. G. & Oishi, K. K. Transgenic plants for therapeutic proteins: linking upstream and downstream technologies. Curr. Top. Microbiol. Immunol. 240, 95-118 (1999).
38. Schillberg, S., Zimmermann, S., Voss, A. & Fischer, R. Apoplastic and cytosolic expression of full-size antibodies and antibody fragments in Nicotiana tabacum. Transgenic Res. 8, 255-263 (1999). This paper compares the stability of identical scFv antibodies that are targeted to different compartments, and shows that the secretory pathway is generally much more suitable for antibody accumulation than the cytosol.
39. De Jaeger, G. et al. High-level accumulation of single-chain variable fragments in the cytosol of transgenic Petunia hybrida. Eur. J. Biochem. 259, 1-10 (1998).
40. Schouten, A., Rossien, J., Bakker, J. & Schots, A. Formation of disulfide bridges by a single-chain Fv antibody in the reducing ectopic environment of the plant cytosol. J. Biol Chem 277, 19339-19345 (2002).
41. Conrad, U. & Fiedler, U. Compartment-specific accumulation of recombinant immunoglobulins in plant cells: an essential tool for antibody production and immunomodulation of physiological functions and pathogen activity. Plant Mol. Biol. 38, 101-109 (1998).
42. Plasterk, R. H. A. & Ketting, R. F. The silence of the genes. Curr. Opin. Genet. Dev. 10, 562-567 (2000).
43. Anandalakshmi, R. et al. A viral suppressor of gene silencing in plants. Proc. Natl Acad. Sci. USA 95, 13079-13084 (1998).
44. Gelvin, S. B. Agrobacterium-mediated plant transformation: the biology behind the "gene-jockeying" tool. Microbiol. Mol. Biol. Rev. 67, 16-23 (2003).
45. Britt, A. B. & May, G. D. Re-engineering plant gene targeting. Trends Plant Sci. 8, 90-95 (2003).
46. Veluthambi, K., Gupta, A. K. & Sharma, A. The current status of plant transformation technologies. Curr. Sci. India 84, 368-380 (2003).
47. Christou, P. Transformation technology. Trends Plant Sci. 1, 423-431 (1996).
48. Twyman, R. M., Stoger, E., Kohli, A. & Christou, P. in Genetic Engineering: Principles and Practice Vol. 24 (ed. Setlow, J. K.) 107-136 (Kluwer-Plenum, New York, 2002).
49. Martineau, B., Voelker, T. A. & Sanders, V. A. On defining T-DNA. Plant Cell 6, 1032-1033 (1994).
50. Hanson, B. et al. A simple method to enrich an Agrobacterium-transformed population for plants containing only T-DNA sequences. Plant J. 19, 727-734 (1999).
51. Fu, X. et al. Linear transgene constructs lacking vector backbone sequences generate low-copy-number transgenic plants with simple integration patterns. Transgenic Res. 9, 11-19 (2000).
52. Lerouge, P., Bardor, M., Pagny, S., Gomord, V. & Faye, L. N-glycosylation of recombinant pharmaceutical glycoproteins produced in transgenic plants: towards humanisation of plant N-glycans. Curr. Pharmaceutical Biotech. 1, 347-354 (2000).
53. Bardor, M. et al. Immunoreactivity in mammals of two typical plant glyco-epitopes: core α(1,3)-fucose and core xylose. Glycobiology 13, 427-434 (2003).
54. Chargelegue, D., Vine, N. D., van Dolleweerd, C. J., Drake, P. M. & Ma, J. K. A murine monoclonal antibody produced in transgenic plants with plant-specific glycans is not immunogenic in mice. Transgenic Res. 9, 187-194 (2000). The first published paper that discusses the immunogenicity of a plant-derived glycosylated recombinant protein.
55. Warner, T. G. in Carbohydrates in Chemistry and Biology (eds Ernst, B., Hart, G. W. & Sanay, P.) 1043-1064 (Wiley, New York, 2000).
56. Blixt, O., Allin, K., Pereira, L., Datta, A. & Paulson, J. C. Efficient chemoenzymatic synthesis of O-linked sialyl oligosaccharides. J. Am. Chem. Soc. 124, 5739-5746 (2002).
57. Bakker, H. et al. Galactose-extended glycans of antibodies produced by transgenic plants. Proc Natl Acad. Sci. USA 98, 2899-2904 (2001). In this study, a transgenic tobacco line that expressed the heavy and light chains of a murine antibody was crossed with a line that expressed human β-1,4-galactosyltransferase. The progeny produced antibodies ∼30% of which had partially galactosylated N-glycans, which provided a useful approach for the 'humanization' of plant glycans.
58. Raju, T. S., Briggs, J., Borge, S. M. & Jones, A. J. S. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 10, 477-486 (2000). In this study, cell-specific glycosylation of immunoglobulins was studied by mass spectrometry and capillary electrophoresis/laser-induced fluorescence in 13 different animal systems. The glycan patterns were found to be unique in different species, which indicated that some might be more suitable than others for the production of human therapeutic proteins. The same might apply to plant systems, which were not considered in this paper.
59. Borisjuk, N. V. et al. Production of recombinant proteins in plant root exudates. Nature Biotechnol. 17, 466-469 (1999).
60. Komarnytsky, S., Borisjuk, N. V., Borisjuk, L. G., Alam, M. Z. & Raskin, I. Production of recombinant proteins in tobacco guttation fluid. Plant Physiol. 124, 927-933 (2000).
61. Drake, P. M. W. et al. Rhizosecretion of a monoclonal antibody protein complex from transgenic tobacco roots. Plant Mol. Biol. 52, 233-241 (2003).
62. Maliga, P. Engineering the plastid genome of higher plants. Curr. Opin. Plant Biol. 5, 164-17212002).
63. Daniell, H., Khan, M. S. & Allison, L. Milestones in chloroplast genetic engineering: an environmentally friendly era in biotechnology. Trends Plant Sci. 7, 84-91 (2002).
64. Tregoning, J. S. et al. Expression of tetanus toxin fragment C in tobacco chloroplasts. Nucleic Acids Res. 31, 1174-1179 (2003).
65. Daniell, H., Lee, S. B., Panchal, T. & Wiebe, P. O. Expression of the native cholera B toxin subunit gene and assembly as functional oligomers in transgenic tobacco chloroplasts J. Mol. Biol. 311, 1001-1009 (2001).
66. Khan, M. S. & Maliga, P. Fluorescent antibiotic resistance marker for tracking plastid transformation in higher plants. Nature Biotechnol. 17, 910-915 (1999).
67. Fischer, R., Emans, N., Schuster, F., Hellwig, S. & Drossard, J. Towards molecular farming in the future: using plant-cell-suspension cultures as bioreactors. Biotechnol. Appl. Biochem. 30, 109-112 (1999).
68. Stöger, E. et al. Practical considerations for pharmaceutical antibody production in different crop systems. Mol. Breeding 9, 149-158 (2002). This paper considers in detail the factors that should be evaluated when choosing a crop system for the production of pharmaceutical proteins. The same scFv is expressed in many species to compare intrinsic yields, and features such as storage, distribution and biosafety are discussed, as well as economic factors.
69. Witcher, D. et al. Commercial production of β-glucuronidase (GUS): a model system for the procluction of proteins in plants. Mol. Breeding 4, 301-312 (1998).
70. Hood, E. E., Woodard, S. L. & Horn, M. E. Monoclonal antibody manufacturing in transgenic plants - myths and realities. Curr. Opin. Biotechnol. 13, 630-635 (2002).
71. Hood, E. E. From green plants to industnal enzymes. Enzyme Microbial. Technol. 30, 279-283 (2002).
72. Zeitlin, L. et al. A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes. Nature Biotechnol. 16, 1361-1364 (1998).
73. Khoudi, H. et al. Production of a diagnostic monoclonal antibody in perennial alfalfa plants. Biotechnol Bioeng 64, 135-143 (1999).
74. Perrin, Y. et al. Transgenic pea seeds as bioreactors for the production of a single-chain Fv fragment (scFV) antibody used in cancer diagnosis and therapy. Mol. Breeding 6, 345-352 (2000).
75. De Wilde, C., Peeters, K., Jacobs, A. Peck, I. & Depicker, A. Expression of antibodies and Fab fragments in transgenic potato plants: a case study for bulk production in crop plants. Mol. Breeding 9, 2871-282 (2002).
76. Schunmann, P. H. D., Coia, G. & Waterhouse, P. M. Biopharming the Simpli-RED™ HIV diagnostic reagent in barley, potato and tobacco. Mol. Breeding 9, 113-121 (2002).
77. McGarvey, P. B. et al. Expression of the rabies virus glycoprotein in transgenic tomatoes. Biotechnology 13, 1484-1487 (1995)
78. Sala, F. et al. Vaccine antigen production in transgenic plants: strategies, gene constructs and perspectives Vaccine 21, 803-808 (2003)
79. Commandeur, U., Twyman, R. M. & Fischer, R. The biosafety of molecular farming in plants AgBiotechNet 5, ABN 110 (2003).
80. Hare, P. D. & Chua, N.-H. Excision of selectable marker genes from transgenic plants. Nature Biotechnol. 20, 575-579 (2002).
81. Zuo, J. R., Niu, Q. W., Ikeda, Y. & Chua, N. H. Marker-free transformation: increasing transformation frequency by the use of regeneration-promoting genes. Curr. Opin. Biotechnol. 13, 173-180 (2002).
82. Eastham, K. & Sweet, J. Genetically Modified Organisms (GMOs): the Significance of Gene Flow through Pollen Transfer. Environment Issue Report No. 28 (European Environment Agency, Copenhagen, 2002)
83. Kay, E., Vogel, T. M., Bertolla, F., Nalin, R. & Simonet, P. In situ transfer of antibiotic resistance genes from transgenic (transplastomic) tobacco plants to bacteria. Appl. Environ. Microbiol. 68, 3345-3351 (2002).
84. Smalla, K. et al. in Proceedings of the 6th International Symposium on the Biosafety of Genetically Modified Organisms 146-154 (Univ. Extension Press, Univ. of Saskatchewan, Canada, 2000).
85. Smyth, S & Phillips, R. W. B. Product differentiation alternatives: identity preservation, segregation and traceability. AgBioForum 5, 30-42 (2002).
86. Schillberg, S., Fischer, R. & Emans, N. Molecular farming of recombinant antibodies in plants. Cell. Mol. Life Sci. 60, 433-445 (2003). This is a comprehensive discussion of the technical issues concerning the production of antibodies in plants, which is treated in much more detail than is possible in the present review.
87. Stoger, E., Sack, M., Fischer, R. & Christou, P. Plantibodies: applications, advantages and bottlenecks. Curr. Opin. Biotechnol. 13, 161-166 (2002).
88. McCormick, A. A. et al. Rapid production of specific vaccines for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants. Proc. Natl Acad. Sci. USA 96, 703-708 (1999).
89. Larrick, J. W., Yu, L., Naftzger, C., Jaiswat, S. & Wycoff, K. Production of secretory IgA antibodies in plants. Biomolecular Eng. 18, 87-94 (2001). This paper presents a useful summary of recent advances in the plant-based production of secretory IgAs with a discussion of purification methods and production costs.
90. Ma, J. K. et al. Characterization of a recombinant plant monoclonal secretory antibody and preventive immunotherapy in humans. Nature Med. 4, 601-605 (1998).
91. Vaquero, C. et al. A carcinoembryonic antigen-specific diabody produced in tobacco. FASEB J. 16, 408-410 (2002).
92. Kathuria, S. et al. Efficacy of plant-produced recombinant antibodies against HCG. Human Reproduction 17, 2054-2061 (2002).
93. Miele, L. Plants as bioreactors for pharmaceuticals: regulatory considerations. Trends Biotechnol. 15, 45-50 (1997).
94. Emlay, D. in Plants as Factories for Protein Production (eds Hood, E. E. & Howard, J.) 175-180 (Kluwer Academic, New York, 2002).
95. Lloyd-Evans, M. & Nair, A. in Biopharming: the Emerging World Market of Plant-based Therapeutics Theta Report No. 1214 63-80 (PJB Medical Publications Inc., New York, 2002).
96. Stoger, E., Schillberg, S., Twyman, R. M., Fischer, R. & Christou, P. in Methods in Molecular Biology. Antibody Engineering. Protocols and Methods 2nd edn (ed. Lo, B. K. C.) (Humana Press Inc., New Jersey. in the press).
97. Schillberg, S., Zimmermann, S., Findlay, K. & Fischer, R. Plasma membrane display of anti-viral single chain Fv fragments confers resistance to tobacco mosaic virus. Mol. Breeding 6, 317-326 (2000).
98. Sijmons, P. C. et al. Production of correctly processed human serum albumin in transgenic plants. Biotechnology 8, 217-221 (1990).
99. Zhu, Z. et al. Expression of human α-interferon in plants. Virology 172, 213-222 (1994).
100. Matsumoto, S., Ikura, K, Ueda, M. & Sasaki, R. Characterisation of a human glycoprotein (erythropoetin) produced in cultured tobacco cells. Plant Mol. Biol. 27, 1163-1172 (1995).
101. Delaney, D. et al. in Plant Biotechnology: 2002 and Beyond. Proceedings of the 10th IAPTC&B Congress, Orlando, Florida. (ed Vasil, I.) 393-394 (Kluwer Academic, Dordrecht. The Netherlands, 2002).
102. Torres, E. et al. Rice cell culture as an alternative production system for functional diagnostic and therapeutic antibodies. Transgenic Res. 8, 441-449 (1999).
103. Terashima, M. et al. Production of functional human α1-antitrypsin by plant cell culture. Appl. Microbiol. Biotechnol. 52, 516-523 (1999).
104. Düring, K., Hippe, S., Kreuzaler, F. & Schell, J. Synthesis and self-assembly of a functional monoclonal antibody in transgenic Nicotiana tabacum. Plant Mol. Biol. 15, 281-293 (1990).
105. Ma, J. K.-C. et al. Generation and assembly of secretory antibodies in plants. Science 268, 716-719 (1995).
106. Francisco, J. A. et al. Expression and characterization of bryodin 1 and a bryodin 1-based single-chain immunotoxin from tobacco cell culture. Bioconjug. Chem. 8, 708-713 (1997).
107. Mayfield, S. P. et al. Expression and assembly of a fully active antibody in algae. Proc. Natl Acad. Sci. USA 100, 438-442 (2003).
108. Streatfield, S. J. et al. Plant-based vaccines: unique advantages. Vaccine 19, 2742-2748 (2001).
109. Ma, S. W. et al. Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance. Nature Med. 3, 793-796 (1997).
110. Yu, J. & Langridge, W. H. A plant-based multicomponent vaccine protects mice from enteric diseases. Nature Biotechnol. 19, 548-552 (2001).
111. Lamphear, B. J. et al. Delivery of subunit vaccines in maize seed. J. Control Release 83, 169-180 (2002).